top of page

Servier's U.S. CEO discusses FDA approval of Voranigo, a targeted therapy for a common type of brain cancer

Aug 7, 2024
1 min read

David Lee describes the glioma brain cancer population this IHD1/2 targeting therapy is for, Servier's experience commercializing cancer medicines, and how he thinks about deals going forward.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page